S1075
Clinical – Upper GI
ESTRO 2026
Purpose/Objective: The efficacy of subsequent-line therapy for advanced liver cancer is limited, and more effective treatment options are urgently needed. Material/Methods: We enrolled patients with advanced liver cancer who had previously received standard therapy. Eligible patients had received at least one systemic treatment for metastatic disease. All enrolled patients received multi-site multimodal radiotherapy. Hypofractioned radiation ( ≥ 5Gy/f) and hypofractioned radiation ( ＜ 3Gy/f) were used according to different tumor load. The combined treatment, including targeted therapy, immunotherapy, and chemotherapy, was selected by the doctor in charge according to the guidelines and the patient 's physical condition. The primary endpoints were safety and efficacy of multi-site multimodal radiotherapy combined with other therapies. Results: A total of 91 patients were enrolled and received trial regimen. Median age was 54 years old, and 85.7% of patients were male. 84.6% of patients had hepatitis history and 81.3% had cirrhosis. Liver metastasis was occurred in 60.4% of patients, distant lymph node metastasis in 51.6%, tumor thrombus in 47.3%, and lung metastasis in 23.1%. In terms of treatment, 69.2%
Conclusion: The addition of multi-site multimodal radiotherapy to subsequent-line treatment is an effective and well- tolerated option for patients with advanced liver cancer. Keywords: multimodal radiotherapy
of patients received multi-site multimodal radiotherapy and targeted therapy plus
Digital Poster 1780
immunotherapy, 13.5% received targeted therapy plus radiation, and 17.6% received immunotherapy plus radiation. The median hypofractionated radiation dose was 40Gy(15-50Gy) and the median conventional fraction radiation dose was 40Gy(20-60Gy). Common grade 1-2 adverse events (AEs) included elevated AST (44.0%), elevated ALT (41.8%), and thrombocytopenia (31.9%). Common grade 3 AEs were anemia (5.5%), thrombocytopenia (4.4%), elevated direct bilirubin (4.4%), and elevated AST (4.4%). Finally, 91 patients received response evaluation. The ORR was 14.3%, and the DCR was 90.1%. Thirteen patients achieved PR and 69 patients were evaluated as SD. The median PFS was 5.47 months (95%CI, 5.17-6.90). The median OS was 11.80 months (95%CI, 8.87-17.20). Waterfall diagram were created according to the time of medication, the best efficacy during the period, the tumor regression and progression (Figure.1).
The prognostic factors of chemoradiotherapy with moderately-hypofractionated intensity modulated radiotherapy for locally advanced pancreatic cancer MICHIO YOSHIMURA, Takahiro Iwai, Yuka Ono, Takashi Mizowaki Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan Purpose/Objective: To evaluate the outcomes and prognostic factors of concurrent chemoradiotherapy using moderately hypofractionated intensity modulated radiotherapy (MHF-IMRT) for locally advanced pancreatic cancer (LAPC). Material/Methods: Patients with LAPC who underwent at least one course of induction chemotherapy (IC), followed by MHF-IMRT with concurrent chemotherapy with a total prescribed dose of 45–51 Gy in 15 fractions between Oct 2010 and Dec 2023 at our hospital were analyzed. CTV was defined as GTV with a margin 5 mm plus the retropancreatic para-aortic lymph nodes (LNs), and PTV was CTV with a margin of 5 mm. PTV–PRV was the
Made with FlippingBook - Share PDF online